GlassScriptPhysician profile
Jacob A Dennington
NPI 1417367145
$5,797.74
in general payments reported to CMS, 2019-2025
37 companies · $1,152 in 2025
The $1,152 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $837 · 2020: $651 · 2021: $351 · 2022: $464 · 2023: $821 · 2024: $1,522 · 2025: $1,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,412 · Education: $83.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,411.52 |
| Education | $83.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $720.19 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $613.46 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $524.41 | 2019-2025 | Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $522.34 | 2019-2025 | Trelegy Ellipta, Bexsero, Shingrix |
| Pfizer INC. | $470.86 | 2021-2025 | |
| Novo Nordisk INC | $448.48 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Supernus Pharmaceuticals, INC. | $319.23 | 2022-2024 | Qelbree, Qelbree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $288.16 | 2019-2025 | Jardiance, Trijardy Xr |
| Allergan, INC. | $190.71 | 2019-2020 | |
| Abbott Laboratories | $183.02 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Medtronic, INC. | $170.44 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $169.43 | 2019-2025 | Trintellix |
| Astellas Pharma US INC | $138.90 | 2019-2024 | Veozah |
| Dynavax Technologies Corporation | $132.25 | 2022-2025 | Heplisav-B |
| Currax Pharmaceuticals LLC | $113.36 | 2023-2025 | Nexletol, Contrave, Nexlizet |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Dennington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.